The U.S. Food and Drug Administration approved the first adjuvanted vaccine for the prevention of H5N1 influenza: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is for use in people 18 years of age and older who are at increased risk of exposure to the H5N1 influenza virus. The H5N1 avian influenza vaccine “is not intended for commercial availability. The U.S. Department of Health and Human Services has purchased the vaccine from the manufacturer, ID Biomedical Corporation of Quebec, Quebec City, Canada (a subsidiary of GlaxoSmithKline Biologicals), for inclusion within the National Stockpile for distribution by public health officials if needed.”
Full FDA NEWS RELEASE, Nov. 22, 2013: